Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

July 31, 2027

Study Completion Date

November 30, 2027

Conditions

Neoplastic DiseaseGlioblastomaGlioblastoma (GBM)Glioblastoma MultiformGlioblastoma Multiforme, AdultGlioblastoma Multiforme (GBM) WHO Grade IV

Interventions

COMBINATION_PRODUCT

TLX-101-Tx + Lomustine

Combination therapy with TLX-101-Tx + Lomustine

RADIATION

TLX101-Tx

Trial Locations (1)

Gold Coast University Hospital, Gold Coast

All Listed Sponsors

lead

Telix Pharmaceuticals (Innovations) Pty Limited

INDUSTRY